1. Lima AR, Martinez PF, Okoshi K, Guizoni DM, Zornoff LA, Campos DH, Oliveira Jr SA, Bonomo C, Dal Pai‐Silva M, Okoshi MP. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure. International journal of experimental pathology. 2010; 91(1):54-62.
2. Kaplan LM, Golden A, Jinnett K, Kolotkin RL, Kyle TK, Look M, Nadglowski J, O'Neil PM, Parry T, Tomaszewski KJ, Stevenin B. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity. 2018; 26(1):61-9.
3. Sutaria S, Devakumar D, Yasuda SS, Das S, Saxena S. Is obesity associated with depression in children? Systematic review and meta-analysis. Archives of disease in childhood. 2019; 104(1):64-74.
4. Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR. Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart. 2015; 101(3):215-21.
5. Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, Pagano F, Schiavon S, Bordin A, Carrizzo A, Vecchione C. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxidative medicine and cellular longevity. 2017; 2017.
6. Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovascular research. 2007; 74(2):184-95.
7. Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. American Journal of Physiology-Heart and Circulatory Physiology. 2008; 295(3):H1206-15.
8. Khan SA, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RC. Rapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes. Journal of molecular and cellular cardiology. 2006; 41(2): 256-64.
9. Das A, Durrant D, Koka S, Salloum FN, Xi L, Kukreja RC. Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice potential role of attenuated oxidative stress and altered contractile protein expression. Journal of Biological Chemistry. 2014; 289(7):4145-60.
10. Hardie DG. AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Current opinion in cell biology. 2015; 33:1-7.
11. Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer letters. 2015; 356(2):165-70.
12. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes. 2006; 55(8):2180-91.
13. Zhai X, Qiao H, Guan W, Li Z, Cheng Y, Jia X, Zhou Y. Curcumin regulates peroxisome proliferator-activated receptor-γ coactivator-1α expression by AMPK pathway in hepatic stellate cells in vitro. European journal of pharmacology. 2015; 746:56-62.
14. Tong W, Wang Q, Sun D, Suo J. Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9. Oncology letters. 2016; 12(5):4139-46.
15. Xiao J, Sheng X, Zhang X, Guo M, Ji X. Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro. Drug design, development and therapy. 2016; 10:1267.
16. Salesi M, Mehrtash M, Daryanoosh F, Tanide N. The Role of Caloric Restriction on Lipid Coat Proteins Gene Expression and Insulin Resistance after 8 Weeks High Caloric Diet in Male Rats. Journal of Arak University of Medical Sciences. 2018; 21(5):21-31.
17. Na LX, Zhang YL, Li Y, Liu LY, Li R, Kong T, Sun CH. Curcumin improves insulin resistance in skeletal muscle of rats. Nutrition, Metabolism and Cardiovascular Diseases. 2011; 21(7):526-33.
18. Li HL, Liu C, De Couto G, Ouzounian M, Sun M, Wang AB, Huang Y, He CW, Shi Y, Chen X, Nghiem MP. Curcumin prevents and reverses murine cardiac hypertrophy. The Journal of clinical investigation. 2008; 118(3):879-93.
19. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L. Curcumin is an inhibitor of p300 histone acetylatransferase. Medicinal chemistry. 2006; 2(2):169-74.
20. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. The Journal of clinical investigation. 2008; 118(3):868-78.
21. Epstein J, Sanderson IR, MacDonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. British journal of nutrition. 2010; 103(11): 1545-57.